Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$11.92M-$11.92MN/M vs Q2 2021 EPS Diluted-$1.37-$1.37N/M vs Q2 2021 Operating Cash Flowderived-$10,686,000N/M Free Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
ended Dec 31, 2021 · filed Feb 14, 2022 · 45 d after period end